US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Direxion NVDA Defined Income Boost ETF

26.79

0.0000

Volume:38

Turnover:996.57

Market Cap:2.41M

PE:- -

High:26.79

Open:26.79

Low:26.79

Close:26.79

52wk High:28.33

52wk Low:24.54

Shares:90.00K

Float Shares:90.00K

Volume Ratio:0.19

T/O Rate:0.04%

Dividend:0.24

Dividend Rate:0.88%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Ribomic Completes Site Network for Phase 3 Achondroplasia Trial in Japan

Moderna’s Shock Rally Redraws the Biotech Playbook

Press Release: 3S Bio Announces 2026 Interim Results: Innovation-Driven, Win-Win Collaboration, and Sustainable Growth

Press Release: Sunshine Guojian Releases 2026 Interim Report:

Regeneron’s Pasatru granted FDA approval for FOP

VOOLT boosts deeptech portfolio with stake in cancer-vaccine biotech Vaxican

BioNTech Highlights Late-Stage Lung Cancer Pipeline Momentum and First Global Data for Pumitamig/Elfetabart Drozuntecan Novel-Novel Combination at WCLC 2026

Arctic Bioscience Sets Date for H1 2026 Results and Investor Webcast

Glenmark Wins U.S. FDA Nod for Generic Flonase Nasal Spray

Memphasys Secures Vietnam Registration for Felix System, Triggers First Major Order

European Equities Traded in the US as American Depositary Receipts Rise in Wednesday Trading

MT Newswires Live

Femasys announces FDA approval of FemBloc modular premarket approval application

Vivoryon Sets Date for 2026 AGM as Kidney Disease Program Advances

Amylyx Phase 3 data support FDA approval, says Citi

Propanc Biopharma starts finalization of clinical trial protocol for PRP study

Cogstate posts record FY26 results and deepens AI-enabled CNS trial platform

Cogstate lifts profit and doubles dividend as clinical trials revenue surges

This Healthcare Stock Could Jump Nearly 40%

Press Release: Enveric Biosciences Reports Financial Results and Provides Corporate Update for Second Quarter 2026

Allarity Therapeutics Reports Second Quarter 2026 Results and Completion of the Phase 3-Ready Stenoparib Manufacturing Campaign

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/stock/NVIB/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"NVIB","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NVIB\",,,,,undefined,":{"symbol":"NVIB","market":"US","secType":"STK","nameCN":"Direxion NVDA Defined Income Boost ETF","latestPrice":26.7855,"timestamp":1787587748415,"preClose":26.7855,"halted":0,"volume":38,"delay":0,"changeRate":0,"floatShares":90001,"shares":90001,"eps":0,"marketStatus":"Trading","change":0,"latestTime":"08-24 13:45:40 EDT","open":26.7855,"high":26.7855,"low":26.7855,"amount":996.5693040000001,"amplitude":0,"askPrice":26.13,"askSize":100,"bidPrice":26.07,"bidSize":100,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1787601600000},"marketStatusCode":2,"adr":0,"listingDate":1785297600000,"exchange":"CBOE","adjPreClose":26.7855,"nav":26.758,"aum":2408282.49,"dividendRate":0.008788,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":27.13,"preClose":26.7855,"latestTime":"16:04 EDT","volume":4,"amount":107.142,"timestamp":1787342650348,"change":0.3445,"changeRate":0.012861,"amplitude":0},"volumeRatio":0.18747},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NVIB\",,,,,undefined,":{"symbol":"NVIB","floatShares":90001,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.18747,"shares":90001,"dividePrice":0.2354,"high":26.7855,"amplitude":0,"preClose":26.7855,"low":26.7855,"week52Low":24.54,"pbRate":"--","week52High":28.3265,"institutionHeld":0,"latestPrice":26.7855,"eps":0,"divideRate":0.008788,"volume":38,"delay":0,"ttmEps":0,"open":26.7855,"prevYearClose":25,"prevWeekClose":26.7855,"prevMonthClose":25.6004,"prevQuarterClose":25,"fiveDayClose":28.15},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NVIB\",params:#limit:5,,,undefined,":[{"date":"2026-08-14","symbol":"NVIB","amount":0.23454,"announcedDate":"2026-08-13","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-08-14","defaultRemindTime":1786714200000,"name":"Direxion NVDA Defined Income Boost ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-08-17","payableDate":"2026-08-14","currency":"USD","dateTimestamp":1786680000000,"payDate":"2026-08-17"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NVIB\",market:\"US\",,,undefined,":[{"executeDate":"2026-08-14","recordDate":"2026-08-14","paymentDate":"2026-08-17","value":0.23454,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"NVIB\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NVIB\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2661226379","title":"Ribomic Completes Site Network for Phase 3 Achondroplasia Trial in Japan","url":"https://stock-news.laohu8.com/highlight/detail?id=2661226379","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661226379?lang=en_us&edition=fundamental","pubTime":"2026-08-24 14:54","pubTimestamp":1787554445,"startTime":"0","endTime":"0","summary":"The latest update is out from Ribomic, Inc. ( ($JP:4591) ). Ribomic has completed the establishment of all planned clinical trial sites for its Pha...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/ribomic-completes-site-network-for-phase-3-achondroplasia-trial-in-japan?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/ribomic-completes-site-network-for-phase-3-achondroplasia-trial-in-japan?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NVIB","GDOC","HYLG","IDNA","MEDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661219445","title":"Moderna’s Shock Rally Redraws the Biotech Playbook","url":"https://stock-news.laohu8.com/highlight/detail?id=2661219445","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661219445?lang=en_us&edition=fundamental","pubTime":"2026-08-22 22:01","pubTimestamp":1787407292,"startTime":"0","endTime":"0","summary":"Moderna ( ($MRNA) ) has risen by 125.15%. Read on to learn why. Moderna has delivered one of the most dramatic moves in biotech this week, with its...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/weekend-updates/modernas-shock-rally-redraws-the-biotech-playbook?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/weekend-updates/modernas-shock-rally-redraws-the-biotech-playbook?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4548","XBIX","BK4534","BK4585","BK4139","BK4532","WDNA","BK4533","BK4581","BK4588","BK4551","NVIB","GNOM","MRNX","MRNA","XBI","MRNY","BK4568","IDNA","LGHT","BK4501"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661250247","title":"Press Release: 3S Bio Announces 2026 Interim Results: Innovation-Driven, Win-Win Collaboration, and Sustainable Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2661250247","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661250247?lang=en_us&edition=fundamental","pubTime":"2026-08-21 15:24","pubTimestamp":1787297040,"startTime":"0","endTime":"0","summary":"SHANGHAI, Aug. 21, 2026 /PRNewswire/ -- 3S Bio (01530.HK) today announced its interim results for the first half of 2026. During the period, the Company recorded revenue of RMB 4.53 billion, represent","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IDNA","BK4232","01530","MEDX","NVIB","BK4022","BK1583","BK1593","HYLG","BK1161","GDOC","R","BMED","HK0000165453.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661258777","title":"Press Release: Sunshine Guojian Releases 2026 Interim Report:","url":"https://stock-news.laohu8.com/highlight/detail?id=2661258777","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661258777?lang=en_us&edition=fundamental","pubTime":"2026-08-21 08:00","pubTimestamp":1787270400,"startTime":"0","endTime":"0","summary":"Innovation-driven, Steady AdvancementSHANGHAI, Aug. 20, 2026 /PRNewswire/ -- Today, Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. (hereinafter referred to as \"Sunshine Guojian\", stock code: 688","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000165453.HKD","R","IDNA","HYLG","BK1593","NVIB","BK4232","01530","MEDX","BK4022","GDOC","BK1161","BK0239","688336","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660287604","title":"Regeneron’s Pasatru granted FDA approval for FOP","url":"https://stock-news.laohu8.com/highlight/detail?id=2660287604","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660287604?lang=en_us&edition=fundamental","pubTime":"2026-08-20 21:20","pubTimestamp":1787232025,"startTime":"0","endTime":"0","summary":"The U.S. Food and Drug Administration has approved Pasatru to reduce new heterotopic ossification and reduce clinician-assessed disease flare-ups i...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/regenerons-pasatru-granted-fda-approval-for-fop-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/regenerons-pasatru-granted-fda-approval-for-fop-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BMED","GNMX","TBXU","IEIH","IBB","MRNY","NVIB","XLVX","BK4588","LABU","GDOC","MEDI","LFSC","FRTY","IYH","RSPH","BK4585","TECB","MRNX","BBP","SYNB","IDNA","PINK","PSCH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660845542","title":"VOOLT boosts deeptech portfolio with stake in cancer-vaccine biotech Vaxican","url":"https://stock-news.laohu8.com/highlight/detail?id=2660845542","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660845542?lang=en_us&edition=fundamental","pubTime":"2026-08-20 20:17","pubTimestamp":1787228270,"startTime":"0","endTime":"0","summary":"The latest update is out from VOOLT Spolka Akcyjna ( ($PL:VLT) ). VOOLT S.A. has signed a preliminary agreement to acquire 108 shares in Polish bio...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/voolt-boosts-deeptech-portfolio-with-stake-in-cancer-vaccine-biotech-vaxican?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/voolt-boosts-deeptech-portfolio-with-stake-in-cancer-vaccine-biotech-vaxican?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NVIB","XBIX","VLT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660288600","title":"BioNTech Highlights Late-Stage Lung Cancer Pipeline Momentum and First Global Data for Pumitamig/Elfetabart Drozuntecan Novel-Novel Combination at WCLC 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2660288600","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660288600?lang=en_us&edition=fundamental","pubTime":"2026-08-20 17:30","pubTimestamp":1787218200,"startTime":"0","endTime":"0","summary":"Pumitamig plus B7H3-targeting elfetabart drozuntecan delivers the first data in lung cancer for any PD-(L)1xVEGF bispecific immunomodulator combined with an antibody-drug conjugate, underscoring BioNT","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/20/3348151/0/en/biontech-highlights-late-stage-lung-cancer-pipeline-momentum-and-first-global-data-for-pumitamig-elfetabart-drozuntecan-novel-novel-combination-at-wclc-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0053666078.USD","MEDX","NVIB","GDOC","BK4107","HYLG","IDNA","LU2487616109.SGD","BK4585","L","BK4588","LU0210528500.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660835402","title":"Arctic Bioscience Sets Date for H1 2026 Results and Investor Webcast","url":"https://stock-news.laohu8.com/highlight/detail?id=2660835402","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660835402?lang=en_us&edition=fundamental","pubTime":"2026-08-20 16:08","pubTimestamp":1787213283,"startTime":"0","endTime":"0","summary":"An announcement from Arctic Bioscience AS ( ($DE:9TD) ) is now available. Arctic Bioscience AS, a biotech company specializing in pharmaceutical an...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/arctic-bioscience-sets-date-for-h1-2026-results-and-investor-webcast?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/arctic-bioscience-sets-date-for-h1-2026-results-and-investor-webcast?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["XBIX","AS","BK4202","NVIB","LNGR","IEIH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660028408","title":"Glenmark Wins U.S. FDA Nod for Generic Flonase Nasal Spray","url":"https://stock-news.laohu8.com/highlight/detail?id=2660028408","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660028408?lang=en_us&edition=fundamental","pubTime":"2026-08-20 12:43","pubTimestamp":1787200984,"startTime":"0","endTime":"0","summary":"Glenmark Pharmaceuticals Limited ( ($IN:GLENMARK) ) just unveiled an announcement. Glenmark Pharmaceuticals has secured U.S. FDA approval for its F...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/glenmark-wins-u-s-fda-nod-for-generic-flonase-nasal-spray?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/glenmark-wins-u-s-fda-nod-for-generic-flonase-nasal-spray?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IYH","BK4585","PSCH","RSPH","TECB","LABU","GNMX","TBXU","MRNX","GDOC","NVIB","PINK","BMED","LFSC","FRTY","IEIH","BBP","BK4588","SYNB","MEDI","IBB","IDNA","XLVX","MRNY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660479252","title":"Memphasys Secures Vietnam Registration for Felix System, Triggers First Major Order","url":"https://stock-news.laohu8.com/highlight/detail?id=2660479252","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660479252?lang=en_us&edition=fundamental","pubTime":"2026-08-20 07:31","pubTimestamp":1787182297,"startTime":"0","endTime":"0","summary":"Memphasys Ltd ( ($AU:MEM) ) has shared an announcement. Memphasys Ltd, an Australian reproductive biotech specialist, is commercialising its Felix ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/memphasys-secures-vietnam-registration-for-felix-system-triggers-first-major-order?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/memphasys-secures-vietnam-registration-for-felix-system-triggers-first-major-order?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MEM","NVIB","XBIX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660421716","title":"European Equities Traded in the US as American Depositary Receipts Rise in Wednesday Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=2660421716","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660421716?lang=en_us&edition=fundamental","pubTime":"2026-08-19 23:18","pubTimestamp":1787152727,"startTime":"0","endTime":"0","summary":"European equities traded in the US as American depositary receipts were tracking higher late Wednesday morning, rising 0.68% to 1,973.64 on the S&P Europe Select ADR Index.From continental Europe, the gainers were led by biotech firm BioNTech  and biopharmaceutical company Grifols , which advanced 24% and 5.6% respectively. They were followed by semiconductor company Sequans Communications  and biopharmaceutical company argenx , which rose 3.3% and 3% respectively.The decliners from continental Europe were led by internet browser company Opera  and biotech firm Evaxion , which fell 7.9% and 6% respectively. They were followed by accommodations booking site Trivago  and telecommunications company Nokia , which were down 4.3% and 1.6% respectively.The gainers from the UK were led by biotech firm Autolus Therapeutics  and mining company BHP Group , which increased 9.2% and 4.5% respectively. They were followed by software firm Endava  and biopharmaceutical company Bicycle Therapeutics , w","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4141","IBB","IE00BMPRXN33.USD","LFGY","IE00BJT1NW94.SGD","BDRX","XBIX","BK4585","SLX","IE00B4R5TH58.HKD","AUTL","DAVA","IE0009355771.USD","GRFS","LU0889565916.HKD","LU2324357040.USD","TRVG","DAVA.AU","SQNS","AFG","BK4547","SNN","LU0006061336.USD","LU0109394709.USD","BK4548","IEUR","EPV","TRIB","ARGX","IE00BJJMRZ35.SGD","LU0823416689.USD","BCYC","NVIB","IE00B2B36J28.USD","BNTX","COAL","FMED","BHP.AU","BHP","OPRA","LU0300736062.USD","NOK","BK4117","PUK","LNOK","BK4588","TBXU","LU0648005311.SGD","EVAX","LU1983260115.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660252964","title":"Femasys announces FDA approval of FemBloc modular premarket approval application","url":"https://stock-news.laohu8.com/highlight/detail?id=2660252964","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660252964?lang=en_us&edition=fundamental","pubTime":"2026-08-19 21:16","pubTimestamp":1787145413,"startTime":"0","endTime":"0","summary":"Femasys (FEMY) announced that the FDA has approved the company’s modular premarket approval application pathway for FemBloc, its investigational no...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/femasys-announces-fda-approval-of-fembloc-modular-premarket-approval-application-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/femasys-announces-fda-approval-of-fembloc-modular-premarket-approval-application-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GDOC","RSPH","XLVX","BK4082","IBB","BBP","PSCH","MRNX","IEIH","LABU","SYNB","TBXU","TECB","MRNY","FEMY","IYH","MEDI","BMED","BK4539","BK4585","IDNA","FRTY","BK4584","LFSC","PINK","BK4588","GNMX","NVIB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660499847","title":"Vivoryon Sets Date for 2026 AGM as Kidney Disease Program Advances","url":"https://stock-news.laohu8.com/highlight/detail?id=2660499847","media":"TIPRANKS","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660499847?lang=en_us&edition=fundamental","pubTime":"2026-08-19 01:02","pubTimestamp":1787072575,"startTime":"0","endTime":"0","summary":"Vivoryon Therapeutics AG ( ($NL:VVY) ) has issued an announcement. Vivoryon Therapeutics N.V., a Germany-based clinical-stage biotech listed on Eur...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/vivoryon-sets-date-for-2026-agm-as-kidney-disease-program-advances?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/vivoryon-sets-date-for-2026-agm-as-kidney-disease-program-advances?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NVIB","BK4195","BBC","BK4229","AGM","XBIX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660595493","title":"Amylyx Phase 3 data support FDA approval, says Citi","url":"https://stock-news.laohu8.com/highlight/detail?id=2660595493","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660595493?lang=en_us&edition=fundamental","pubTime":"2026-08-18 22:05","pubTimestamp":1787061936,"startTime":"0","endTime":"0","summary":"Citi says Amylyx’s (AMLX) avexitide showed a “highly differentiated” profile in the Phase 3 LUCIDITY study, a 78 participant, placebo-controlled tr...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/amylyx-phase-3-data-support-fda-approval-says-citi-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/amylyx-phase-3-data-support-fda-approval-says-citi-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IBB","IDNA","IEIH","BK4585","TECB","PINK","MRNX","SYNB","LFSC","MEDI","RSPH","IYH","LABU","BBP","FRTY","MRNY","BK4007","NVIB","XLVX","GNMX","BMED","AMLX","BK4588","GDOC","TBXU","PSCH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660608394","title":"Propanc Biopharma starts finalization of clinical trial protocol for PRP study","url":"https://stock-news.laohu8.com/highlight/detail?id=2660608394","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660608394?lang=en_us&edition=fundamental","pubTime":"2026-08-18 20:50","pubTimestamp":1787057418,"startTime":"0","endTime":"0","summary":"Propanc Biopharma (PPCB) announced it has commenced finalization of a clinical trial protocol and will conduct a feasibility assessment for its fir...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/propanc-biopharma-starts-finalization-of-clinical-trial-protocol-for-prp-study-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/propanc-biopharma-starts-finalization-of-clinical-trial-protocol-for-prp-study-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NVIB","PPCB","MEDX","HYLG","BK4139","IDNA","GDOC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660443063","title":"Cogstate posts record FY26 results and deepens AI-enabled CNS trial platform","url":"https://stock-news.laohu8.com/highlight/detail?id=2660443063","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660443063?lang=en_us&edition=fundamental","pubTime":"2026-08-18 06:49","pubTimestamp":1787006950,"startTime":"0","endTime":"0","summary":"Cogstate Ltd ( ($AU:CGS) ) has shared an update. Cogstate Ltd is a science-led clinical trial endpoint specialist focused on central nervous system...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/cogstate-posts-record-fy26-results-and-deepens-ai-enabled-cns-trial-platform?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/cogstate-posts-record-fy26-results-and-deepens-ai-enabled-cns-trial-platform?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4135","IDNA","ARTY","HYLG","CNS","NVIB","AIPO","QTOC","CHAT","GDOC","AGIX","MEDX","VTHR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660306364","title":"Cogstate lifts profit and doubles dividend as clinical trials revenue surges","url":"https://stock-news.laohu8.com/highlight/detail?id=2660306364","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660306364?lang=en_us&edition=fundamental","pubTime":"2026-08-18 06:48","pubTimestamp":1787006906,"startTime":"0","endTime":"0","summary":"Cogstate Ltd ( ($AU:CGS) ) has provided an announcement. Cogstate Ltd, a provider of digital cognitive assessment solutions for global clinical tri...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/cogstate-lifts-profit-and-doubles-dividend-as-clinical-trials-revenue-surges?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/cogstate-lifts-profit-and-doubles-dividend-as-clinical-trials-revenue-surges?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["VIG","GDOC","HYLG","NVIB","MEDX","IDNA","BMED"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659983127","title":"This Healthcare Stock Could Jump Nearly 40%","url":"https://stock-news.laohu8.com/highlight/detail?id=2659983127","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659983127?lang=en_us&edition=fundamental","pubTime":"2026-08-15 09:30","pubTimestamp":1786757400,"startTime":"0","endTime":"0","summary":"Medpace has carved out a niche helping smaller biotech companies navigate the complicated regulatory process. By Todd ChankoBy the time any of us stop by our local pharmacy to pick up a medication, th","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0029874061.USD","BK4588","LU0130103400.USD","IQV","LU1791710582.SGD","LU1989764664.SGD","LU2065171402.SGD","BK4581","LU0477156797.USD","LU1791710400.SGD","LU2065170008.USD","LU2065169927.USD","BK4530","LU2065171311.SGD","BK4121","LU0130102774.USD","LABU","FTRE","LU0648001328.SGD","NVIB","XLV","LU0528227936.USD","MEDP","HEAL","LU0128526141.USD","LU0130517989.USD","HCSG","EKG","LU0477156953.USD","LU0648000940.SGD","LU0882574055.USD","BK4585","LU0980610538.SGD","LU1201861165.SGD","LU1201861249.SGD","LU1989764748.USD","LU0198837287.USD","XBI","BK4137","LU0130518102.USD","LU1261432733.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659126775","title":"Press Release: Enveric Biosciences Reports Financial Results and Provides Corporate Update for Second Quarter 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2659126775","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659126775?lang=en_us&edition=fundamental","pubTime":"2026-08-15 04:05","pubTimestamp":1786737900,"startTime":"0","endTime":"0","summary":"EB-003 Development Highlights:--  Continued advancing IND-enabling studies supporting the planned. submission of an Investigational New Drug  application for EB-003. --  Reported preclinical data demonstrating that EB-003 consistently. exhibited a non-hallucinogenic profile in a highly sensitive. --  Announced promising results from preclinical in vitro experiments. indicating no photoreactive potential for EB-003, further derisking its. continued development as a potential treatment of neuropsychiatric. --  Initiated genotoxicity studies to evaluate the potential for EB-003 to. interact with DNA and cause genetic mutations, a critical measure of. --  Secured U.S. Patent No. 12,605,361 pertaining to the Company's EVM301. Series of molecules being developed as potential treatments for mental","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GDOC","BK4604","BK4585","03160","BK4555","TM","MEDX","BK4099","IND","HYLG","ENVB","IDNA","BK4588","BK4007","NVIB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659141595","title":"Allarity Therapeutics Reports Second Quarter 2026 Results and Completion of the Phase 3-Ready Stenoparib Manufacturing Campaign","url":"https://stock-news.laohu8.com/highlight/detail?id=2659141595","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659141595?lang=en_us&edition=fundamental","pubTime":"2026-08-14 20:00","pubTimestamp":1786708800,"startTime":"0","endTime":"0","summary":"- Completed quarter with $26.9 million in cash and restricted cash - Key U.S. patent was awarded, protecting exclusivity of stenoparib when used with the stenoparib-specific DRP companion diagnostic i","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/14/3345276/0/en/allarity-therapeutics-reports-second-quarter-2026-results-and-completion-of-the-phase-3-ready-stenoparib-manufacturing-campaign.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GDOC","BK4539","LENZ","BK4503","API","BK4023","ALLR","PLTM","CLIA","IDNA","BK4139","BK4551","CDMO","BK4007","NVIB","BMED","BK4535"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":6,"pageCount":1,"totalSize":104,"code":"91000000","status":"200"}]}}